Compare Stocks: ONCY, CMPX, PRTC, and RCKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.18 -1.4%	$2.22	$1.61 ▼ $6.88	$397.99M	0.95	2.48 million shs	2.61 million shs
ONCY Oncolytics Biotech	$0.80 -1.2%	$0.84	$0.73 ▼ $1.51	$102.65M	1.15	658,384 shs	739,533 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RCKT Rocket Pharmaceuticals	$3.63 -2.2%	$3.58	$2.53 ▼ $5.45	$407.26M	0.5	1.23 million shs	871,424 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-1.36%	-10.29%	-1.80%	+8.46%	-37.36%
ONCY Oncolytics Biotech	-1.85%	-9.66%	-0.97%	-3.05%	-42.81%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+3.54%
RCKT Rocket Pharmaceuticals	-2.16%	-5.96%	-0.27%	+36.47%	+13.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.18 -1.4%	$2.22	$1.61 ▼ $6.88	$397.99M	0.95	2.48 million shs	2.61 million shs
ONCY Oncolytics Biotech	$0.80 -1.2%	$0.84	$0.73 ▼ $1.51	$102.65M	1.15	658,384 shs	739,533 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RCKT Rocket Pharmaceuticals	$3.63 -2.2%	$3.58	$2.53 ▼ $5.45	$407.26M	0.5	1.23 million shs	871,424 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-1.36%	-10.29%	-1.80%	+8.46%	-37.36%
ONCY Oncolytics Biotech	-1.85%	-9.66%	-0.97%	-3.05%	-42.81%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+3.54%
RCKT Rocket Pharmaceuticals	-2.16%	-5.96%	-0.27%	+36.47%	+13.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	439.87% Upside
ONCY Oncolytics Biotech	2.67	Moderate Buy	$5.00	528.93% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	136.13% Upside

Current Analyst Ratings Breakdown

Latest ONCY, CMPX, PRTC, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/19/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	461.88	N/A	N/A	$1.11 per share	1.96
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	-2,185.97%	-442.99%	11/11/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)

Latest ONCY, CMPX, PRTC, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	11.22	11.22
ONCY Oncolytics Biotech	N/A	1.35	1.35
PRTC PureTech Health	N/A	6.59	6.59
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
ONCY Oncolytics Biotech	6.82%
PRTC PureTech Health	0.04%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	18.70%
ONCY Oncolytics Biotech	0.10%
PRTC PureTech Health	5.30%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
ONCY Oncolytics Biotech	30	127.51 million	127.38 million	Not Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable

ONCY, CMPX, PRTC, and RCKT Headlines

Recent News About These Companies

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

September 9 at 12:31 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Coverage Initiated at Chardan Capital

September 3, 2026 | americanbankingnews.com

BlackRock Inc. Invests $33.94 Million in Rocket Pharmaceuticals, Inc. $RCKT

September 2, 2026 | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 1, 2026 | marketbeat.com

Ieq Capital LLC Invests $1.51 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKT

August 26, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts

August 21, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,493 Shares of Stock

August 18, 2026 | insidertrades.com

Rocket Pharmaceuticals' General Counsel Martin Wilson Sells Shares to Cover RSU Tax Obligations

August 17, 2026 | kalkinemedia.comK

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock

August 17, 2026 | marketbeat.com

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells 4,701 Shares

August 14, 2026 | insidertrades.com

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

August 11, 2026 | zacks.com

Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

August 11, 2026 | marketbeat.com

Rocket Pharmaceuticals: Q2 Earnings Snapshot

August 11, 2026 | aol.comA

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

August 3, 2026 | benzinga.com

Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?

July 29, 2026 | seekingalpha.com

Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

June 25, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, CMPX, PRTC, and RCKT Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.18 -0.03 (-1.36%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$2.19 +0.01 (+0.69%)

As of 09/9/2026 07:53 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Oncolytics Biotech NASDAQ:ONCY

$0.80 -0.01 (-1.24%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.03 (+3.27%)

As of 09/9/2026 07:55 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 09/8/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.63 -0.08 (-2.16%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.71 +0.08 (+2.23%)

As of 09/9/2026 07:57 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, CMPX, PRTC, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, CMPX, PRTC, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, CMPX, PRTC, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, CMPX, PRTC, and RCKT Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Oncolytics Biotech NASDAQ:ONCY

PureTech Health NASDAQ:PRTC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, CMPX, PRTC, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, CMPX, PRTC, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, CMPX, PRTC, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, CMPX, PRTC, and RCKT Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Oncolytics Biotech NASDAQ:ONCY

PureTech Health NASDAQ:PRTC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools